Home Stock

Stock Research: Divi's Laboratories

Independent, rules-based stock research to judge this stock's true performance: Cut through market noise and find high-growth or high-value gems from 8,000+ stocks worldwide.

Divi's Laboratories

NSI:DIVISLAB INE361B01024
19
  • Value
    11
  • Growth
    79
  • Safety
    Safety
    99
  • Combined
    37
  • Sentiment
    10
  • 360° View
    360° View
    19
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

Divi's Laboratories Limited is an India-based company engaged in pharmaceutical ingredients, intermediates, and nutraceutical ingredients with a focus on exports and custom synthesis. Its main businesses include manufacturing active pharmaceutical ingredients (APIs) and intermediates, and providing contract manufacturing services for global innovator companies across various therapeutic areas. The company operates in India and has subsidiaries in the USA and Europe. In the last fiscal year, the company had a market cap of $21095 million, profits of $587 million, revenue of $1095 million, and 18300 employees.

more

ANALYSIS: With an Obermatt 360° View of 19 (better than 19% compared with alternatives), overall professional sentiment and financial characteristics for the stock Divi's Laboratories are critical, mostly below average. The 360° View is based on consolidating four consolidated indicators, with half of the metrics below and half above average for Divi's Laboratories. The consolidated Growth Rank has a good rank of 79, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth as well as stock returns. This means that growth is higher than for 79% of competitors in the same industry. In addition, the consolidated Safety Rank has a safer rank of 99 which means that the company has a financing structure that is safer than 99% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. But the consolidated Value Rank has a less desirable rank of 11 which means that the share price of Divi's Laboratories is on the higher side compared with typical size in indicators such as revenues, profits, and invested capital. This means that the stock price is higher than for 89% of alternative stocks in the same industry. The consolidated Sentiment Rank also has a low rank of 10, which means that professional investors are more pessimistic about the stock than for 90% of alternative investment opportunities. ...read more

more
Strongest Rank Market Pulse
Weakest Rank Safety
Country India
Industry Life Sciences Tools & Services
Size Large
Website divislabs.com
Index
Divi's Laboratories stock price by TradingView. Not sourced by Obermatt.
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 13-Mar-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Value
Identifies how good a value the stock is.
Good Value Expensive
Combined
Consolidated view across Value, Growth, and Safety.
Good Tread Carefully
Growth
Shows a company's growth potential.
High Growth Tough Times
Sentiment
Shows what the market thinks of a stock.
Positive Sentiment Skepticism
Safety
Safety
Assesses how financially secure a company is.
Well-Financed High Leverage
360° View
360° View
Holistic stock analysis: all key non-/financial metrics
Good Watch Out

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
11 5 11 15
Growth
79 81 43 81
Safety
Safety
99 99 100 100
Sentiment
10 67 49 6
360° View
360° View
19 19 59 53
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
29 7 1 27
Opinions Change
50 94 50 17
Pro Holdings
n/a 81 73 40
Market Pulse
1 60 64 55
Sentiment
10 67 49 6
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
11 5 11 15
Growth
79 81 43 81
Safety Safety
99 99 100 100
Combined
37 37 55 87
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
1 1 5 3
Price vs. Earnings (P/E)
8 5 12 22
Price vs. Book (P/B)
10 14 28 20
Dividend Yield
49 31 39 44
Value
11 5 11 15
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
65 84 74 76
Profit Growth
77 74 34 63
Capital Growth
82 14 50 70
Stock Returns
49 99 37 65
Growth
79 81 43 81
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
93 100 96 100
Refinancing
32 42 50 40
Liquidity
93 100 98 100
Safety Safety
99 99 100 100

Similar Stocks

Discover high‑ranked alternatives to Divi's Laboratories and broaden your portfolio horizons.

SBI Life Insurance

NSI:SBILIFE
Country: India
Industry: Life & Health Insurance
Size: Large
Full Stock Analysis

CESC

NSI:CESC
Country: India
Industry: Electric Utilities
Size: Medium
Full Stock Analysis

Infosys

NSI:INFY
Country: India
Industry: IT Consulting & oth. Services
Size: XX-Large
Full Stock Analysis

Bharat Petroleum

NSI:BPCL
Country: India
Industry: Oil & Gas Refining
Size: X-Large
Full Stock Analysis

Frequently Asked
Questions

The company has high growth and safe financing but is expensive (low Value Rank) and has low market sentiment. This is a warning that the stock may be too expensive. This is for an experienced growth investor willing to risk overpaying, but only after conducting thorough research on future growth potential.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

OTHER FEATURES

Use the Platform to its Fullest

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing:

Review us See More Google Reviews